Dexmedetomidine-Propofol and Ketamine-Propofol During Upper Gastrointestinal System Sedation
Brief Summary
Sedation with dexmedetomidine-propofol or ketamine-propofol was planned in patients with upper gastrointestinal endoscopy.
Study Design
Study type: | Observational |
---|---|
Status: | Completed |
Study results: | No Results Available |
Age: | 18 Years to 60 Years (Adult) |
Enrollment: | 60 () |
Funded by: | Other |
Masking |
Clinical Trial Dates
Start date: | Oct 18, 2019 | |
---|---|---|
Primary Completion: | Feb 20, 2020 | |
Completion Date: | Mar 13, 2020 | |
Study First Posted: | May 22, 2020 | |
Results First Posted: | Aug 31, 2020 | |
Last Updated: | May 22, 2020 |
Sponsors / Collaborators
Lead Sponsor:
N/A
Responsible Party:
N/A
Location
Patients between 18 and 60 years in American Society of Anesthesiologists (ASA) I and II groups were included. Patients that had severe organ disease, allergies to study drugs, refused to participate in the study were excluded. Cases were randomized into the dexmedetomidine-propofol group (Group D, n=30) and ketamine-propofol group (Group K, n=30). Cardiac monitoring, peripheral oxygen saturation, bispectral index (BIS) monitoring were performed. Group D received 1mg/kg dexmedetomidine+0.5mg/kg propofol intravenous (iv) bolus, 0.5 μg/kg/h dexmedetomidine+ 0.5 mg/kg/h propfol infusion. Group K received 0.125 mL/kg bolus, 0.125 mL/kg/h ketamine+ propofol = ketofol infusion (ketofol was prepared with 4 mg propofol+2 mg ketamine). Patients were followed up with a Ramsay Sedation Scale (RSS) ofâ¥4. Mean, standard deviation, mean, lowest-highest frequency and ratio values were used in descriptive statistics of the data, SPSS 22.0 program was used for the analyses.
Eligibility Criteria
Sex: | All |
---|---|
Minimum Age: | 18 |
Maximum Age: | 60 |
More Details
NCT Number: | NCT04399226 |
---|---|
Other IDs: | umutkan |
Study URL: | https://ClinicalTrials.gov/show/NCT04399226 |
Last updated: Jun 17, 2022